GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Belite Bio Inc (NAS:BLTE) » Definitions » Net Margin %

Belite Bio (Belite Bio) Net Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Belite Bio Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Belite Bio's Net Income for the three months ended in Mar. 2024 was $-7.87 Mil. Belite Bio's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Belite Bio's net margin for the quarter that ended in Mar. 2024 was 0.00%.

The historical rank and industry rank for Belite Bio's Net Margin % or its related term are showing as below:


BLTE's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -150.095
* Ranked among companies with meaningful Net Margin % only.

Belite Bio Net Margin % Historical Data

The historical data trend for Belite Bio's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Belite Bio Net Margin % Chart

Belite Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Net Margin %
- - - -

Belite Bio Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Belite Bio's Net Margin %

For the Biotechnology subindustry, Belite Bio's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Belite Bio's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Belite Bio's Net Margin % distribution charts can be found below:

* The bar in red indicates where Belite Bio's Net Margin % falls into.



Belite Bio Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Belite Bio's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-31.632/0
= %

Belite Bio's Net Margin for the quarter that ended in Mar. 2024 is calculated as

Net Margin=Net Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-7.871/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Belite Bio  (NAS:BLTE) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Belite Bio Net Margin % Related Terms

Thank you for viewing the detailed overview of Belite Bio's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Belite Bio (Belite Bio) Business Description

Traded in Other Exchanges
Address
12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.